Synthesis, Characterization, and Examination of Possible Anticancer Effects of a Novel Bis-1,2,3-triazole derivative via Molecular Docking Studies

Ayşe Tan

doi:10.17776/csj.1717866

Synthesis, Characterization, and Examination of Possible Anticancer Effects of a Novel Bis-1,2,3-triazole derivative via Molecular Docking Studies

Abstract

A new bis-1,2,3-triazole compound (6) was synthesized by utilizing Cu(I)-catalyzed azide-alkyne cycloaddition (CuAAC) method and characterized by ¹H, ¹³C NMR, and HR-(ESI)-MS analysis. Molecular docking studies against EGFR, mTOR, and p70S6K1 receptor proteins were performed to examine the potential anticancer effects of 6. The inhibition of these receptors has been considered an important therapeutic strategy in anticancer studies. The docking results were compared with those of anastrozole, which is an anticancer drug, and co-crystallized ligands of EGFR, mTOR, and p70S6K1 receptors, which are FMM for EGFR, P2X for mTOR, and 5FI for p70S6K1. The co-crystallized ligands are highly effective inhibitors for the receptors. According to the docking studies, compound 6 has quite good binding affinities with the three receptors. The best binding energy values with mTOR, p70S6K1, and EGFR of 6 are calculated as -10.38 kcal/mol, -9.93 kcal/mol, and -10.02 kcal/mol, respectively. Conversely, anastrozole’s best binding values are -8.42 kcal/mol, -8.08 kcal/mol, and -7.55 kcal/mol, respectively. On the other hand, when compared to the binding energies of FMM (−13.16 kcal/mol, P2X (−8.81 kcal/mol), and 5FI(−7.6 kcal/mol), it is seen that compound 6 has better binding energy than them, except for FMM. The EIC (Estimated Inhibition Constant) Ki values with mTOR, p70S6K1, and EGFR of 6 are found as 24.81 nM, 52.21 nM, and 45.28 nM, respectively, while anastrozole’s Ki values are 671.53 nM, 1190 nM, and 2950 nM. On the other hand, the Ki values of P2X, 5FI, and FMM are 347 nM, 2700 nM, and 25.5 nM, respectively. These results show that compound 6 has much better binding energy than anastrozole, P2X, and 5FI. Therefore, the compound may show considerable inhibitory effects against these receptor proteins and could be considered a potential candidate drug for anticancer studies.

Keywords

Thanks

The author is thankful to Mus Alparslan University

References

Kolcuoglu, Y., Bekircan, O., Fazli, H., Sahin, E., Ture, A., Akdemir, A., & Hamarat Sanlier, S. (2023). Design and synthesis of new heterocyclic compounds containing 5-[(1 H-1, 2, 4-triazol-1-yl) methyl]-3 H-1, 2, 4-triazole-3-thione structure as potent hEGFR inhibitors. Journal of Biomolecular Structure and Dynamics, 41(22), 12753-12767. https://doi.org/10.1080/07391102.2023.2167113
Baykara, O. (2016). Kanser Tedavisinde Güncel Yaklaşımlar. Balıkesir Sağlık Bilimleri Dergisi, 5(3), 154-165. https://izlik.org/JA99RR39DX
Yokoyama, M., Miyauchi, M., Yamada, N., Okano, T., Sakurai, Y., Kataoka, K., & Inoue, S. (1990). Characterization and anticancer activity of the micelle-forming polymeric anticancer drug adriamycin-conjugated poly (ethylene glycol)-poly (aspartic acid) block copolymer. Cancer research, 50(6), 1693-1700.
Sibilia, M., Kroismayr, R., Lichtenberger, B. M., Natarajan, A., Hecking, M., & Holcmann, M. (2007). The epidermal growth factor receptor: from development to tumorigenesis. Differentiation, 75(9), 770-787. https://doi.org/10.1111/j.1432-0436.2007.00238.x
Kattan, S. W., Nafie, M. S., Elmgeed, G. A., Alelwani, W., Badar, M., & Tantawy, M. A. (2020). Molecular docking, anti-proliferative activity and induction of apoptosis in human liver cancer cells treated with androstane derivatives: Implication of PI3K/AKT/mTOR pathway. The Journal of Steroid Biochemistry and Molecular Biology, 198, 105604. https://doi.org/10.1016/j.jsbmb.2020.105604
Tan, A., Köse, A., Mete, D., Şanlı-Mohamed, G., Kishalı, N. H., & Kara, Y. (2023). Investigation of cytotoxic properties of some isoindole-related compounds bearing silyl and azide groups with in vitro and in silico studies. Phosphorus, Sulfur, and Silicon and the Related Elements, 198(11), 933-942. https://doi.org/10.1080/10426507.2023.2232509
Schlessinger, J. (2000). Cell signaling by receptor tyrosine kinases. Cell, 103(2), 211-225. DOI: 10.1016/S0092-8674(00)00114-8
Sigismund, S., Avanzato, D., & Lanzetti, L. (2018). Emerging functions of the EGFR in cancer. Molecular oncology, 12(1), 3-20. doi: 10.1002/1878-0261.12155

Shaban, N., Kamashev, D., Emelianova, A., & Buzdin, A. (2023). Targeted inhibitors of EGFR: structure, biology, biomarkers, and clinical applications. Cells, 13(1), 47. https://doi.org/10.3390/cells13010047
Ballou, L. M., & Lin, R. Z. (2008). Rapamycin and mTOR kinase inhibitors. Journal of chemical biology, 1(1), 27-36. DOI: 10.1007/s12154-008-0003-5
Huang, S. (2020). mTOR signaling in metabolism and cancer. Cells, 9(10), 2278. https://doi.org/10.3390/cells9102278
Bahrami-B, F., Ataie-Kachoie, P., Pourgholami, M.H., & Morris, D.L. (2014). p70 Ribosomal protein S6 kinase (Rps6kb1): an update. Journal of clinical pathology, 67(12), 1019-1025. https://doi.org/10.1136/jclinpath-2014-202560
Tan, A., & Noma, S. A. A. (2024). Novel hybrid compounds containing 1, 2, 3-triazole and naphthalene subunits as xanthine oxidase inhibitors. Journal of the Iranian Chemical Society, 21(8), 2249-2258. https://doi.org/10.1007/s13738-024-03061-3
Lazrek, H., Taourirte, M., Oulih, T., Barascut, J., Imbach, J., Pannecouque, C., Witrouw, M., & De Clercq, E. (2001). Synthesis and anti-HIV activity of new modified 1, 2, 3-triazole acyclonucleosides. Nucleosides, Nucleotides and Nucleic Acids, 20(12), 1949-1960. DOI: 10.1081/NCN-100108325
He, Y.-W., Dong, C.-Z., Zhao, J.-Y., Ma, L.-L., Li, Y.-H., & Aisa, H. A. (2014). 1, 2, 3-Triazole-containing derivatives of rupestonic acid: click-chemical synthesis and antiviral activities against influenza viruses. European Journal of Medicinal Chemistry, 76, 245-255. https://doi.org/10.1016/j.ejmech.2014.02.029
Aher, N. G., Pore, V. S., Mishra, N. N., Kumar, A., Shukla, P. K., Sharma, A., & Bhat, M. K. (2009). Synthesis and antifungal activity of 1, 2, 3-triazole containing fluconazole analogues. Bioorganic & medicinal chemistry letters, 19(3), 759-763. https://doi.org/10.1016/j.bmcl.2008.12.026
El Malah, T., Nour, H. F., Satti, A. A., Hemdan, B. A., & El-Sayed, W. A. (2020). Design, synthesis, and antimicrobial activities of 1, 2, 3-triazole glycoside clickamers. Molecules, 25(4), 790. https://doi.org/10.3390/molecules25040790
Tan, A., & Almaz, Z. (2023). A series of 1, 2, 3-triazole compounds: Synthesis, characterization, and investigation of the cholinesterase inhibitory properties via in vitro and in silico studies. Journal of Molecular Structure, 1277, 134854. https://doi.org/10.1016/j.molstruc.2022.134854
Kim, T. W., Yong, Y., Shin, S. Y., Jung, H., Park, K. H., Lee, Y. H., Lim, Y., & Jung, K.-Y. (2015). Synthesis and biological evaluation of phenyl-1H-1, 2, 3-triazole derivatives as anti-inflammatory agents. Bioorganic chemistry, 59, 1-11. https://doi.org/10.1016/j.bioorg.2015.01.003
Sayeed, I. B., Vishnuvardhan, M., Nagarajan, A., Kantevari, S., & Kamal, A. (2018). Imidazopyridine linked triazoles as tubulin inhibitors, effectively triggering apoptosis in lung cancer cell line. Bioorganic Chemistry, 80, 714-720. https://doi.org/10.1016/j.bioorg.2018.07.026
da Silva, V. D., de Faria, B. M., Colombo, E., Ascari, L., Freitas, G. P., Flores, L. S., Cordeiro, Y., Romão, L., Buarque, C. D. (2019). Design, synthesis, structural characterization and in vitro evaluation of new 1, 4-disubstituted-1, 2, 3-triazole derivatives against glioblastoma cells. Bioorganic Chemistry, 83, 87-97. https://doi.org/10.1016/j.bioorg.2018.10.003
Khan, M. F., Anwer, T., Bakht, A., Verma, G., Akhtar, W., Alam, M. M., Rivzi, M.A., Akhter, M., Shaquiquzzaman, M. (2019). Unveiling novel diphenyl-1H-pyrazole based acrylates tethered to 1, 2, 3-triazole as promising apoptosis inducing cytotoxic and anti-inflammatory agents. Bioorganic Chemistry, 87, 667-678. https://doi.org/10.1016/j.bioorg.2019.03.071
Srivastava, A., Aggarwal, L., & Jain, N. (2015). One-pot sequential alkynylation and cycloaddition: regioselective construction and biological evaluation of novel benzoxazole–triazole derivatives. ACS Combinatorial Science, 17(1), 39-48. https://doi.org/10.1021/co500135z
Aouad, M. R., Almehmadi, M. A., Rezki, N., Al-blewi, F. F., Messali, M., & Ali, I. (2019). Design, click synthesis, anticancer screening and docking studies of novel benzothiazole-1, 2, 3-triazoles appended with some bioactive benzofused heterocycles. Journal of Molecular Structure, 1188, 153-164. https://doi.org/10.1016/j.molstruc.2019.04.005
Zhai, H., Li, D., Li, M., Zou, J., Liu, F., Chen, F., Yan, X., Liu, Y., & Zhou, W. (2020). Acylation modification of konjac glucomannan and its adsorption of Fe (III) ion. Carbohydrate Research, 497, 108133. https://doi.org/10.1016/j.carres.2020.108133
Gahlaut, P. S., Gautam, D., Lama, P., & Jana, B. (2023). Unusual coordination of a 1, 2, 3-triazolyl-pyridine ligand in a Pd (ii) complex: application in the Suzuki–Miyaura coupling reaction. New Journal of Chemistry, 47(14), 6871-6879. https://doi.org/10.1039/D3NJ00206C
Berman, H. M., Westbrook, J., Feng, Z., Gilliland, G., Bhat, T. N., Weissig, H., Shindyalov, I. N., Bourne, P. E. (2000). The protein data bank. Nucleic acids research, 28(1), 235-242. https://doi.org/10.1093/nar/28.1.235
Morris, G. M., Huey, R., Lindstrom, W., Sanner, M. F., Belew, R. K., Goodsell, D. S., & Olson, A. J. (2009). AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. Journal of computational chemistry, 30(16), 2785-2791. https://doi.org/10.1002/jcc.21256
Dassault Systèmes BIOVIA, Discovery Studio Modeling Environment, Release , San Diego: Dassault Systèmes, https://www.3ds.com/products/biovia/discovery-studio
Rostovtsev, V. V., Green, L. G., Fokin, V. V., & Sharpless, K. B. (2002). A stepwise huisgen cycloaddition process: copper (I)-catalyzed regioselective “ligation” of azides and terminal alkynes. Angewandte Chemie International Edition, 41(14), 2596-2599. doi: 10.1002/1521-3773(20020715)41:14<2596::AID-ANIE2596>3.0.CO;2-4
Mirjafary, Z., Mohammad Karbasi, M., Hesamzadeh, P., Shaker, H. R., Amiri, A., & Saeidian, H. (2022). Novel 1, 2, 3-triazole-based benzothiazole derivatives: Efficient synthesis, DFT, molecular docking, and ADMET studies. Molecules, 27(23), 8555. https://doi.org/10.3390/molecules27238555
El Azab, I. H., El-Sheshtawy, H. S., Bakr, R. B., & Elkanzi, N. A. (2021). New 1, 2, 3-triazole-containing hybrids as antitumor candidates: design, click reaction synthesis, DFT calculations, and molecular docking study. Molecules, 26(3), 708. https://doi.org/10.3390/molecules26030708
Ghosh, D., Rhodes, S., Hawkins, K., Winder, D., Atkinson, A., Ming, W., Padgett, C., Orvis, J., Aiken, K., Landge, S. (2015). A simple and effective 1, 2, 3-triazole based “turn-on” fluorescence sensor for the detection of anions. New Journal of Chemistry, 39(1), 295-303. DOI: 10.1039/C4NJ01411A
Wood, E. R., Truesdale, A. T., McDonald, O. B., Yuan, D., Hassell, A., Dickerson, S. H., Ellis, B., Pennisi, C., Horne, E., Lackey, K., Alligood, K.J., Rusnak, D.W., Gilmer, T.M., Shewchuk, L. (2004). A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib) relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer research, 64(18), 6652-6659. https://doi.org/10.1158/0008-5472.CAN-04-1168
Montemurro, F., Valabrega, G., & Aglietta, M. (2007). Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity. Expert opinion on biological therapy, 7(2), 257-268. https://doi.org/10.1517/14712598.7.2.257
Yang, H., Rudge, D. G., Koos, J. D., Vaidialingam, B., Yang, H. J., & Pavletich, N. P. (2013). mTOR kinase structure, mechanism and regulation. Nature, 497(7448), 217-223. https://doi.org/10.1038/nature12122
Thornton, A., Komati, R., Kim, H., Myers, J., Petty, K., Sam, R., Johnson-Henderson, E., Reese, K., Tran, L., Sridhar, V., Williams, C., &Sridhar, J. (2024). Development of 6-amido-4-aminoisoindolyn-1, 3-diones as p70S6K1 inhibitors and potential breast cancer therapeutics. Frontiers in Molecular Biosciences, 11, 1481912. https://doi.org/10.3389/fmolb.2024.1481912
Wheler, J. J., Moulder, S. L., Naing, A., Janku, F., Piha-Paul, S. A., Falchook, G. S., Zinner, R., Tsimberidou, A.M., Fu, S., Hong, D.S., Atkins, J.T., Yelensky, R., Stephens, P.J., &Kurzrock, R. (2014). Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway. Oncotarget, 5(10), 3029-3038. doi: 10.18632/oncotarget.1799
Polychronis, A., Sinnett, H. D., Hadjiminas, D., Singhal, H., Mansi, J. L., Shivapatham, D., Shousha, S., Jiang, J., Petson, D., Barrett, N., Vigushin, D., Morrison, K., Beresford, E., Ali, S., Slade, M.J., & Coombes, R.C. (2005). Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial. The lancet oncology, 6(6), 383-391. DOI: 10.1016/S1470-2045(05)70176-5

Details

Primary Language

English

Subjects

Organic Chemistry (Other) , Theoretical and Computational Chemistry (Other)

Journal Section

Research Article

Authors

Ayşe Tan ^*
0000-0003-2692-7923
Türkiye

Publication Date

April 29, 2026

Submission Date

June 12, 2025

Acceptance Date

March 28, 2026

Published in Issue

Year 2026 Volume: 47 Number: 2

DOI

https://doi.org/10.17776/csj.1717866

IZ

https://izlik.org/JA56NJ85BE

Cite

RIS / Bibtex

APA

Tan, A. (2026). Synthesis, Characterization, and Examination of Possible Anticancer Effects of a Novel Bis-1,2,3-triazole derivative via Molecular Docking Studies. Cumhuriyet Science Journal, 47(2), 320-328. https://doi.org/10.17776/csj.1717866